araag2/HINT huggingface dataset:
Clinical trial NCT01336205 (phase 3, status: completed)
Conditions: opioid-induced constipation (oic)
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: nktr-118, usual care
SMILES: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent prior to any study-specific procedures.

          -  NEW PATIENTS ONLY: Self-reported active symptoms of OIC at screening (<3 SBMs/week and
             experiencing >1 reported symptom of hard/lumpy stools, straining, or sensation of
             incomplete evacuation/anorectal obstruction in at least 25% of the BMs over the
             previous 4 weeks); and Documented confirmed OIC (<3 SBMs/week on average over the
             2-week OIC confirmation period.

          -  PATIENTS ENROLLING FROM OTHER NKTR-118 STUDIES: Receiving a stable maintenance opioid
             regimen consisting of a total daily dose of 30 mg to 1000 mg or oral morphine, or
             equianalgesic amount(s) of 1 or more opioid therapies.

          -  FOR PATIENTS RANDOMIZED TO RECEIVE NKTR-118: Willingness to stop all laxatives and
             other bowel regimens including prune juice and herbal products throughout the 52-week
             treatment period, and to use only bisacodyl as rescue medication if BM has not
             occurred within at least 72 hours of the last recorded BM.

        Exclusion Criteria:

          -  Patients receiving Opioid regimen for treatment of pain related to cancer.

          -  History of cancer within 5 years from first study visit with the exception of basal
             cell cancer and squamous cell skin cancer.

          -  Medical conditions and treatments associated with diarrhea, intermittent loose stools,
             or constipation.

          -  Other issues related to the gastrointestinal tract that could impose a risk to the
             patient.

          -  Pregnancy or lactation.
Clinical trial NCT00528879 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, placebo, metformin
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria

          -  Males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic
             control

          -  Participants who have been receiving metformin at a total daily dose ≥1500 mg per day
             for at least 8 weeks

          -  C-peptide ≥1.0 ng/mL

          -  Body mass index ≤45.0 kg/m^2

          -  Serum creatinine level <1.50 mg/dL for men or <1.40 mg/dL for women.

        Key Exclusion Criteria

          -  Aspartate aminotransferase and/or alanine aminotransferase level >3.0 times the upper
             limit of normal

          -  Serum total bilirubin level >2 mg/dL

          -  Creatinine kinase level >3 times upper limit of normal

          -  Symptoms of severely uncontrolled diabetes

          -  Serum creatinine level ≥1.50 mg/dL for men or ≥1.40 mg/dL for women

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic,
             endocrine, psychiatric, or rheumatic diseases
Clinical trial NCT00460512 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Participant meets the Diagnostic and Statistical Manual of Mental Disorders (Edition
             4) criteria for schizophrenia

          -  Participant is previously non-acute (on the same antipsychotic medication used for the
             treatment of schizophrenia and Clinical Global Impression-Severity [CGI-S] change less
             than or equal to 1 in the past 4 weeks before enrollment) and has been given an
             adequate dose of an appropriate oral antipsychotic for an adequate period of time
             prior to enrollment, but previous treatment is considered unsuccessful due to one or
             more of the following reasons: lack of effectiveness, lack of tolerability or safety,
             lack of compliance and/or other reasons to switch to another antipsychotic medication

          -  Participant is healthy on the basis of a physical examination and vital signs at
             screening

          -  Female participants must be postmenopausal for at least 1 year, surgically sterile,
             abstinent, or, if sexually active, agree to practice an effective method of birth
             control before entry and throughout the study

          -  Participants must be willing and able to fill out self-administered questionnaires

        Exclusion Criteria:

          -  Participants on clozapine, any conventional depot neuroleptic or risperidone
             long-acting injection during the last 3 months

          -  Participants with serious unstable medical condition, including known clinically
             relevant laboratory abnormalities

          -  Participants with history or current symptoms of tardive dyskinesia (twitching or
             jerking movements that you cannot control in your face, tongue, or other parts of your
             body) and neuroleptic malignant syndrome (high fever, rigid muscles, shaking,
             confusion, sweating more than usual, increased heart rate or blood pressure, or muscle
             pain or weakness)

          -  Participants judged to be at high risk for adverse events, violence or self-harm

          -  Participants with a current use or known history (over the past 6 months) of substance
             dependence according to Diagnostic and Statistical Manual of Mental Disorders (Edition
             4) Criteria
Clinical trial NCT01181895 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: vilanterol, salmeterol inhalation powder, placebo inhalation powder ndpi, placebo inhalation powder diskus
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatient at least 12 years of age

          -  Both genders; females of childbearing potential must be willing to use birth control
             method

          -  Clinical diagnosis of asthma for ≥12 weeks

          -  Best pre-bronchodilator FEV1 of 40%-90% predicted

          -  Reversibility of FEV1 of at least 12% and 200mls

          -  Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks
             prior to 1st visit

          -  Ability to use replace current short-acting rescue treatment with albuterol and
             ability to withhold albuterol use for at least 6 hours prior to study visits

        Exclusion Criteria:

          -  History of life-threatening asthma

          -  Respiratory infection within last 4 weeks leading to change in asthma management

          -  Asthma exacerbation within last 3 months

          -  Concurrent respiratory disease or other disease that would confound study
             participation or affect subject safety

          -  Allergies to study drugs, study drugs' excipients, or medications related to study
             drugs

          -  Taking another investigational medication or medication prohibited for use during the
             study.

          -  Previous participation in a vilanterol (GW642444) study
Clinical trial NCT01289782 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: placebo, tmc435, peginterferon alpha-2a (pegifn alpha-2a), ribavirin (rbv)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Genotype 1 hepatitis C infection (confirmed at screening)

          -  Patient has not received any prior treatment for hepatitis C

          -  Patient must have had a liver biopsy within 3 years before screening (or between the
             screening and baseline visit) showing chronic hepatitis C infection

          -  Must agree to use 2 forms of effective contraception throughout study (both males and
             females)

        Exclusion Criteria:

          -  Infection with HIV or non genotype 1 hepatitis C

          -  Liver disease not related to hepatitic C infection

          -  Hepatic decompensation

          -  Significant laboratory abnormalities or other active diseases

          -  Pregnant or planning to become pregnant
Clinical trial NCT00559351 (phase 3, status: terminated)
Conditions: esophageal neoplasms, squamous cell cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10, C96.20, C96.29, D47.09
Drugs: neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    difficulty in recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  Histopathologically proven, clinically stage II-III (cTNM according to AJCC/UICC
             classification), primary squamous cell carcinoma of the thoracic esophagus

          -  Patients' age above 18 years

          -  General condition with Karnofsky performance status of >70

          -  Circulatory and pulmonary capacity at normal range (FEV1 >60%; FVC >60%, NYHA I-II,
             cardiac output >40%)

          -  Normal function of the bone marrow (RBC >3,5 T/l; PLT >100 G/l)

          -  Normal renal (creatinine <1.5 of the upper limit) and liver (AST or ALT <2,5 of the
             upper limit or bilirubin <1,5 of the upper limit) function

        Exclusion Criteria:

          -  Metastatic disease

          -  Synchronous malignancy

          -  History of other cancer within 5 years prior to esophageal cancer treatment

          -  History of allergic reaction to cisplatin of 5-fluorouracil

          -  Systemic infection

          -  Pregnancy or female patients in childbearing age without proper contraceptives.
Clinical trial NCT00311311 (phase 3, status: terminated)
Conditions: atherosclerosis, kidney failure
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83, N19, T86.12, N17.8, N17.9, O90.4, N99.0, N17.0
Drugs: tacrolimus, mycophenolate mofetil, prednisone, sirolimus, tacrolimus, mycophenolate mofetil, prednisone
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

        At least one of the following characteristics:

          -  History of dialysis for at least 3 years.

          -  History of diabetes for at least 5 years.

          -  Hypertension or ischemic nephropathy as a cause of the end stage renal disease or loss
             of the first transplant.

          -  History of coronary artery disease, stroke, myocardial infarction, or amputation for
             vascular disease.

        Exclusion Criteria:

          -  History of malignancy within the last 5 years (except adequately treated skin cancer).

          -  Recipients of non-renal organ transplant.

          -  Active gastrointestinal disease that may interfere with drug absorption.

          -  Active HIV, hepatitis B or C infection.

          -  Women who are pregnant or breastfeeding.
Clinical trial NCT01457911 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: glimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490)
SMILES: [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Chinese patients with type 2 diabetes mellitus, as defined by World Health
             Organization, diagnosed for at least 1 year at the time of screening visit and
             inadequately controlled with metformin

          -  Signed written informed consent

        Exclusion criteria:

          -  Type 1 diabetes mellitus

          -  HbA1c < 7% or > 10%

          -  Fasting plasma glucose > 250 mg/dL (> 13.9 mmol/L)

          -  Age <18 years or Age ≥ 80 years

          -  Patients who have not been on stable daily dose of at least 1500 mg metformin within 3
             months prior to screening

          -  Patients currently receiving or who have received anti-diabetic drugs other than
             metformin within 3 months prior to screening

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00420212 (phase 3, status: completed)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: bg00012, placebo
SMILES: [H]\C(=C(\[H])C(=O)OC)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Unless otherwise specified, to be eligible to participate in this study, candidates
             must meet the following eligibility criteria at the time of the randomization:

          -  Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4.

          -  Must have a baseline EDSS between 0.0 and 5.0, inclusive.

          -  Must have relapsing-remitting disease course.

        Key Exclusion Criteria:

          -  Unless otherwise specified, candidates will be excluded from study entry if any of the
             following exclusion criteria exist at randomization:

          -  Other chronic disease of the immune system, malignancies, acute urologic, pulmonary,
             gastrointestinal disease.

          -  Pregnant or nursing women.

        Note: Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00234832 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: sibutramine hydrochloride, placebo, sibutramine hydrochloride
SMILES: CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject's body mass index (BMI) was >= 27 kg/m(2) and <= 45 kg/m(2) or their BMI was
             >= 25 kg/m(2) and < 27 kg/m(2) with waist circumference of >= 102 cm in males or >= 88
             cm in females.

          -  Medical history positive for:

               -  Preexisting cardiovascular disease (i.e., coronary artery disease,
                  cerebrovascular disease, or peripheral arterial occlusive disease) and/or

               -  Type 2 diabetes mellitus with at least 1 other risk factor (i.e., dyslipidemia,
                  controlled hypertension, current smoker, or diabetic nephropathy with evidence of
                  microalbuminuria)

        Exclusion Criteria:

          -  History of recent myocardial infarction.

          -  Heart failure symptoms greater than New York Heart Association Functional Class II.

          -  Hemodynamically significant valvular or left ventricular (LV) tract obstruction.

          -  Subjects without a pacemaker and with any of the following:

               -  Sinus bradycardia (< 50 bpm)

               -  Sick sinus syndrome

               -  Atrioventricular block of more than 1st degree

          -  Mean sitting systolic blood pressure (SBP) > 160 mmHg. Mean sitting diastolic blood
             pressure (DBP) > 100 mmHg. Mean sitting heart rate (HR) > 100 bpm.

          -  Syncopal episodes presumed to be due to uncontrolled life-threatening arrhythmias.

          -  Planned cardiac surgery or coronary angioplasty within 6 months of screening.

          -  History of recent non-hemorrhagic stroke or transient ischemic attack (TIA), history
             of hemorrhagic stroke.

          -  Hyperthyroidism.

          -  Known chronic liver disease or endstage renal disease.

          -  Severe, symptomatic benign prostatic hyperplasia which may require surgery.

          -  Known pheochromocytoma, history of narrow angle glaucoma, Gilles de la Tourette
             syndrome, history of seizures, history of bariatric or abdominal obesity surgery
             (excluding liposuction).

          -  Concomitant use of monoamine oxidase inhibitors or drugs that increase levels of
             serotonin in the brain.

          -  Treated hypertension stabilized for less than 3 months.

          -  Inability to perform regular physical activity.
Clinical trial NCT00319306 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Aged over 18

          -  Confirmed diagnosis of mild to moderate asthma by doctor

          -  Currently receiving inhaled corticoid-steroid medicine for treatment of asthma and
             requiring a review of current asthma treatment

        Exclusion Criteria:

          -  Women who are pregnant, breast-feeding, or planning pregnancy

          -  Patients with a history of chronic obstructive pulmonary disease

          -  Patients using any beta blocker therapy

          -  Patients receiving steroid tablets or steroid injections
Clinical trial NCT00501046 (phase 3, status: completed)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: placebo, ast-120
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [C]
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  Moderate to severe CKD, not anticipated to require dialysis or renal transplant within
             the next 6 months

          -  Patient survival expected to be no less than one year

          -  Serum creatinine in men >= 2.0 mg/dL (>= 177 µmol/L) and <= 5.0 mg/dL (<= 442 µmol/L),
             and in women >= 1.5 mg/dL (>= 133 µmol/L) and <= 5.0 mg/dL (<= 442 µmol/L) at
             Screening

          -  Urinary total protein to urinary total creatinine ratio must be >= 0.5 on a spot void
             obtained at Screening

          -  Blood pressure <= 160/90 mmHg at both Screening and Baseline visits. In addition,
             blood pressure, if measured, must have been stable in hypertensive patients over the 3
             months prior to Screening, with no more than 1 blood pressure reading > 160/90 mmHg

          -  In patients being treated for hypertension, they should be on a stable
             anti-hypertensive regimen

        Exclusion Criteria:

          -  Obstructive or reversible cause of kidney disease

          -  Nephrotic syndrome defined as a ratio of urinary total protein to urinary creatinine
             of > 6.0 as measured on a spot void

          -  Adult polycystic kidney disease

          -  History of previous kidney transplant

          -  History of recent (within the past 6 months) accelerated or malignant hypertension

          -  Uncontrolled arrhythmia or severe cardiac disease within the past 6 months

          -  History of malabsorption, inflammatory bowel disease, hiatal hernia, active peptic
             ulcer, or severe GI dysmotility, not attributable to the use of a phosphate binder

          -  Received any investigational agent or participated in a clinical study within the
             previous 3 months

          -  Presence of any significant medical condition that might create an undue risk with
             study participation, or significantly confound the collection of safety and efficacy
             data in this study
Clinical trial NCT00441103 (phase 3, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: rebif® new formulation (ifn-beta-1a, rnf), placebo, rebif® new formulation (ifn-beta-1a, rnf)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females between 18 and 60 years of age

          -  Female subjects must be neither pregnant nor breast-feeding and must lack
             child-bearing potential, as defined by either: post-menopausal or surgically sterile
             or use an effective method of contraception for the duration of the study

          -  Have Relapsing Remitting Multiple Sclerosis (RRMS) according to the revised McDonald
             criteria 2005

          -  Have brain and/or spinal MRI with findings typical of Multiple Sclerosis (MS)

          -  Have disease duration for more than 12 months

          -  Have disease activity characterized by at least one clinical event and one or more
             Gadolinium-enhancing MRI lesions within the 6 months prior to randomization

          -  Have score of <=5.5 on the Expanded Disability Status Scale (EDSS)

          -  Be willing and able to comply with the protocol for the duration of the study

          -  Have given written informed consent prior to any study-related procedure not part of
             the normal medical practice

        Exclusion Criteria:

          -  Have any disease other than MS that could better explain his/her signs and symptoms

          -  Have complete transverse myelitis or bilateral optic neuritis

          -  Have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or
             immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic
             hormone [ACTH]), or total lymphoid irradiation

          -  Have received within 3 months prior to baseline any approved disease-modifying therapy
             for MS, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis,
             any investigational drug, or experimental procedure

          -  Have received within 30 days prior to baseline oral or systemic corticosteroids or
             ACTH

          -  Other protocol defined exclusion criteria could apply